Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
6 hedge funds and large institutions have $458K invested in Rosetta Genomics Ltd. in 2017 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
45% more capital invested
Capital invested by funds: $315K → $458K (+$143K)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
33% less funds holding
Funds holding: 9 → 6 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$34K |
| 2 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$1.39K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $381K | +$222K | +99,899 | +160% |
|
|
HCM
2
Highlander Capital Management
Short Hills,
New Jersey
| $76K | -$1.39K | -626 | -2% |
|
3
SEI Investments
Oaks,
Pennsylvania
| $1K | – | – | – |
|
|
VKH
4
Virtu KCG Holdings
New York
| – | -$34K | -11,425 | Closed |
|
ROSG Hedge Fund Activity: Q2 2017 in Review
6 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q2 2017, worth a combined $458K — up 45% from $315K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ROSG and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $222K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $34K sold.
- 6 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q2 2017, down from 9 in Q1 2017.
- Funds reported $458K of Rosetta Genomics Ltd. stock for Q2 2017, up 45% quarter-over-quarter.
- 0 funds opened new Rosetta Genomics Ltd. positions in Q2 2017 and 3 closed out, a net change of -3 holders.
- The largest Rosetta Genomics Ltd. buyer in Q2 2017 was Morgan Stanley, an estimated $222K added.
- The largest Rosetta Genomics Ltd. seller in Q2 2017 was Virtu KCG Holdings, an estimated $34K sold.
Based on aggregated 13F filings for Q2 2017.